273 related articles for article (PubMed ID: 15166968)
41. Peritoneovenous shunt for intractable ascites of hepatic, nephrogenic, and malignant causes.
Holm A; Halpern NB; Aldrete JS
Am J Surg; 1989 Aug; 158(2):162-6. PubMed ID: 2757146
[TBL] [Abstract][Full Text] [Related]
42. Incrementally Expandable Transjugular Intrahepatic Portosystemic Shunts: Single-Center Experience.
Cui J; Smolinski SE; Liu F; Xu D; Dulaimy K; Irani Z
AJR Am J Roentgenol; 2018 Feb; 210(2):438-446. PubMed ID: 29261352
[TBL] [Abstract][Full Text] [Related]
43. Covered stents are better than uncovered stents for transjugular intrahepatic portosystemic shunts in cirrhotic patients with refractory ascites: a retrospective cohort study.
Maleux G; Perez-Gutierrez NA; Evrard S; Mroue A; Le Moine O; Laleman W; Nevens F
Acta Gastroenterol Belg; 2010; 73(3):336-41. PubMed ID: 21086935
[TBL] [Abstract][Full Text] [Related]
44. Complications of Denver peritoneovenous shunting.
Lund RH; Moritz MW
Arch Surg; 1982 Jul; 117(7):924-8. PubMed ID: 6979992
[TBL] [Abstract][Full Text] [Related]
45. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding.
Lo GH; Liang HL; Chen WC; Chen MH; Lai KH; Hsu PI; Lin CK; Chan HH; Pan HB
Endoscopy; 2007 Aug; 39(8):679-85. PubMed ID: 17661241
[TBL] [Abstract][Full Text] [Related]
46. Transjugular intrahepatic portosystemic shunt: an analysis of outcomes.
Kurmis TP
ANZ J Surg; 2009 Oct; 79(10):745-9. PubMed ID: 19878172
[TBL] [Abstract][Full Text] [Related]
47. A new nitinol monofilament stent: early experience with use for transjugular intrahepatic portosystemic shunts.
Yoon CJ; Chung JW; Kim HB; Lee JW; Park JH
Cardiovasc Intervent Radiol; 2002; 25(3):200-4. PubMed ID: 12058215
[TBL] [Abstract][Full Text] [Related]
48. Treatment of Chylous Ascites with Peritoneovenous Shunt (Denver Shunt) following Retroperitoneal Lymph Node Dissection in Patients with Urological Malignancies: Update of Efficacy and Predictors of Complications.
Yarmohammadi H; Schilsky J; Durack JC; Brody LA; Asenbaum U; Velayati S; Santos E; Gonzalez-Aguirre AJ; Erinjeri JP; Petre N; Solomon SB; Sheinfeld J; Getrajdman GI
J Urol; 2020 Oct; 204(4):818-823. PubMed ID: 32364837
[TBL] [Abstract][Full Text] [Related]
49. Bizarre complications of peritoneovenous shunts.
Eckhauser FE; Strodel WE; Girardy JW; Turcotte JG
Ann Surg; 1981 Feb; 193(2):180-4. PubMed ID: 7469552
[TBL] [Abstract][Full Text] [Related]
50. Peritoneovenous shunts palliate malignant ascites.
Edney JA; Hill A; Armstrong D
Am J Surg; 1989 Dec; 158(6):598-601. PubMed ID: 2480068
[TBL] [Abstract][Full Text] [Related]
51. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.
Bureau C; Thabut D; Oberti F; Dharancy S; Carbonell N; Bouvier A; Mathurin P; Otal P; Cabarrou P; Péron JM; Vinel JP
Gastroenterology; 2017 Jan; 152(1):157-163. PubMed ID: 27663604
[TBL] [Abstract][Full Text] [Related]
52. Mitigation of Sarcopenia after Peritoneovenous Shunt Placement in Patients with Refractory Ascites.
Currie BM; Bakhtiar M; Nadolski GJ; Soulen MC
J Vasc Interv Radiol; 2023 Apr; 34(4):633-638. PubMed ID: 36563934
[TBL] [Abstract][Full Text] [Related]
53. Saphenoperitoneal shunts for patients with intractable ascites associated with chronic liver disease.
Vadeyar HJ; Doran JD; Charnley R; Ryder SD
Br J Surg; 1999 Jul; 86(7):882-5. PubMed ID: 10417558
[TBL] [Abstract][Full Text] [Related]
54. Peritoneovenous shunts in malignant ascites.
Helzberg JH; Greenberger NJ
Dig Dis Sci; 1985 Nov; 30(11):1104-7. PubMed ID: 2996864
[TBL] [Abstract][Full Text] [Related]
55. Long-term results and quality of life in patients treated with transjugular intrahepatic portosystemic shunts.
Zhuang ZW; Teng GJ; Jeffery RF; Gemery JM; Janne d'Othee B; Bettmann MA
AJR Am J Roentgenol; 2002 Dec; 179(6):1597-603. PubMed ID: 12438061
[TBL] [Abstract][Full Text] [Related]
56. Transjugular intrahepatic portosystemic shunts: long-term patency and clinical results in a patient cohort observed for 3-9 years.
ter Borg PC; Hollemans M; Van Buuren HR; Vleggaar FP; Groeneweg M; Hop WC; Laméris JS
Radiology; 2004 May; 231(2):537-45. PubMed ID: 15044746
[TBL] [Abstract][Full Text] [Related]
57. Palliation of malignant ascites by the Denver peritoneovenous shunt.
Downing R; Black J; Windsor CW
Ann R Coll Surg Engl; 1984 Sep; 66(5):340-3. PubMed ID: 6207757
[TBL] [Abstract][Full Text] [Related]
58. Peritoneovenous shunt in malignant ascites. The Bordet Institute experience from 1975-1998.
Tueche SG; Pector JC
Hepatogastroenterology; 2000; 47(35):1322-4. PubMed ID: 11100342
[TBL] [Abstract][Full Text] [Related]
59. Predictors of Shunt Dysfunction and Overall Survival in Patients with Variceal Bleeding Treated with Transjugular Portosystemic Shunt Creation Using the Fluency Stent Graft.
Wan YM; Li YH; Xu Y; Wu HM; Li YC; Wu XN; Yang JH
Acad Radiol; 2018 Jul; 25(7):925-934. PubMed ID: 29373208
[TBL] [Abstract][Full Text] [Related]
60. The Denver type for peritoneovenous shunting of malignant ascites.
Roussel JG; Kroon BB; Hart GA
Surg Gynecol Obstet; 1986 Mar; 162(3):235-40. PubMed ID: 2420017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
